BioNet Recombinant Pertussis Vaccine Submitted to EMA

BioNet’s Recombinant Pertussis Vaccine Submitted to European Medicines Agency (EMA) “Monovalent recombinant acellular pertussis vaccine proven to significantly boost immunity against pertussis” Lyon, France – July 31, 2024, BioNet Europe, the French subsidiary of BioNet, a vaccine manufacturer specializing in the development of genetically engineered vaccines, has announced the submission of a centralized Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for its monovalent Recombinant Pertussis Vaccine (RPV). BioNet’s stand-alone vaccine targets whooping cough, a highly contagious respiratory disease on the steep rise across Europe. This non-combined vaccine is tailored to the persons who require pertussis-only booster vaccination and are up-to-date with their diphtheria and tetanus immunizations. Dr Giuseppe Del Giudice, Director Translational Research at BioNet, stated: “BioNet’s recombinant vaccine is designed to provide more effective and longer-lasting immune protection against pertussis than traditional acellular pertussis vaccines. It contains a Pertussis Toxin (PT), the main component responsible for severe pertussis disease, which is inactivated by recombinant technologies rather than chemicals.” These recombinant technologies allow for the preservation of the native structure of the PT, fundamental for the induction of higher immune protection. Currently, no other monovalent or recombinant pertussis vaccines are available in Europe, making BioNet’s RPV a best-in-class vaccine driving significant advancement in public health with the potential to improve acceptance for pertussis immunization. Phillippe Guillot-Chene, CEO of BioNet Europe, added, “We believe that BioNet’s RPV represents a transformative vaccine for preventing pertussis disease. After receiving the positive feedback from EMA Scientific Advice, we are honored to have our MAA submission validated by the EMA as well.” The safety, immunogenicity and antibody persistence induced after one single booster dose of BioNet’s RPV were demonstrated in numerous randomized clinical trials, notably amongst adults in Australia, adolescents in Switzerland, as well as vulnerable populations such as pregnant women and elderly in Thailand. The vaccine is licensed in Asia (under the Pertagen® trademark) and is included in the pertussis maternal immunization program for pregnant women in Thailand. The MAA of Pertagen® has also been submitted to the Australian Therapeutic Goods Administration. About BioNet BioNet is a vaccine manufacturer specializing in the development of recombinant and mRNA vaccines against respiratory diseases and other global public health threats. BioNet has a strong track record with development and biomanufacturing, having advanced over three proprietary recombinant pertussis vaccines from early R&D to licensure. It currently markets multiple vaccines through its established commercial network. BioNet has been rapidly expanding its operations across Asia, Europe and North America. Media Contacts Europe: Benoit Soubeyrand, [email protected] Asia-Pacific: Laurent Dapremont, [email protected] North America: Bill Cadwallader, [email protected] +1.206.852.0307 Website: bionet.one and bionet-asia.com Forward-Looking Statements This press release contains forward-looking statements relating to BioNet’s business, including regulatory submissions. These statements are based on current expectations as of the date of this press release and involve known and unknown risks and uncertainties that may cause actual results to differ materially. BioNet disclaims any intention or obligation to publicly update or revise any forward-looking statements, whether due to new information, future events, or otherwise. Search News categories BioNet News (29) Events (8) Biotech News (60) Thailand (2) Covid-19 (2) News tags Acellular Pertussis Vaccine (5) Adolescent (3) AI (3) aP (5) Artificial Intelligence (5) biotechnology (12) booster vaccine (3) Bordetella pertussis (9) cancer (8) Cancer vaccine (5) covid-19 (22) COVID-19 vaccine (3) Diphtheria (7) DNA (3) Flu (3) genetically detoxified pertussis toxin (6) Immune Response (8) immune system (12) Immunization (5) immunoginicity (5) infectious disease (4) infectious diseases (4) maternal immunization (3) mRNA (14) mRNA Technology (7) pandemic (8) Pertussis (9) Pertussis Toxin (4) pertussis vaccine (5) PT (5) PTgen (5) respiratory diseases (4) RNA (4) SARS-CoV-2 (8) Tdap (8) tetanus (6) Tuberculosis (3) vaccination (10) vaccine (35) Vaccine Development (10) vaccines (4) Vaccine Storage (3) virus (3) Whooping Cough (8) Whoopingcough (4) Recent News Hybrid Nanocarriers Could Enable Targeted Vaccine Delivery in the Lungs January 22, 2026 The golden age of vaccine development January 19, 2026 The European Commission Grants Marketing Authorisation for a First-of-its-Kind Pertussis-Only Vaccine for Vaccination of Teenagers, Adults and Pregnant Women in the European Union January 15, 2026 New Pertussis Vaccine Set for Implementation December 20, 2025 BioNet Receives Positive CHMP Opinion from EMA for VacPertagen, a Recombinant Vaccine Against Pertussis November 21, 2025 Subscribe Terms of use Privacy 2026© BioNet-Asia. All rights reserved. We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok

The release as fetched from its publisher. bionet-asia.com ↗